BioXplor is developing an AI- and network-based drug-discovery platform for pharma and biotech, which will prioritize drug combinations for complex diseases. The platform prioritizes single assets or entire drug pipelines, with a unique safety- and efficacy-based prioritization model for multiple drug targets and drug combination candidates. In response to the pandemic, BioXplor is positioning the platform for antiviral and anti-inflammatory COVID-19 drug combinations, which it will leverage to build a pipeline of biotech and academic partners and clients.